Effects of Pro12Ala Polymorphism of Peroxisome Proliferator-Activated Receptor Γ2 (pparγ2) Gene on the Therapeutic Efficacy of Rosiglitazone in Impaired Glucose Regulation and Type 2 Diabetes

项洁,胡云,童国玉,扬东辉,徐小华,朱大龙
DOI: https://doi.org/10.3321/j.issn:1006-6187.2008.06.014
2008-01-01
Abstract:Objective To examine the effects of the Pro12Ala polymorphism of PPAR γ2 gene on the therapeutic efficacy of rosiglitazone(RGZ)in patients with impaired glucose regulation(IGR)or newly diagnosed type 2 diabetes(T2DM).Methods A total of 106 patients with IGR or newly diagnosed T2DM were treated with RGZ(4 mg/d)for 12 weeks without withdrawing the previous medications.All patients were genotyped for the PPARγ2 Pro12Ala polymorphism by PCR-RFLP.Results The Ala12 allele frequency was 3.7%.Of the 106 patients,98(92.5%)had the PP genotype and 8(7.5%)had the PA genotype.The AA genotype was not observed.The magnitudes of decreases in fasting plasma glucose and hemoglobin A1c level were significantly greater in PA genotype than in PP genotype(t=-2.254,P=0.026;t=-2.227,P=0.028 respectively).In addition,the decrease in HOMA-IR level was significantly greater in PA genotype than in PP genotype(t=-4.083,P=0.000).Conclusions The IGR and T2DM patients with PA genotype in the PPAR γ2 gene had a better therapeutic response to RGZ than did patients with PP genotype
What problem does this paper attempt to address?